Gilead expands voluntary licensing agreements for once-yearly Yeztugo (GILD:NASDAQ)

Dr Reddy’s inks licensing deal with Gilead for once-yearly HIV lenacapavir

Dr Reddy’s signs royalty-free, non-exclusive voluntary licence with Gilead for investigational once-yearly lenacapavir PrEP in 120 high-incidence countries.

Dr. Reddy’s expands Gilead pact for HIV prevention drug

Dr. Reddy’s Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).

Gilead expands voluntary licensing agreements for once-yearly Yeztugo (GILD:NASDAQ)

Gilead adds once-yearly Yeztugo (lenacapavir) HIV PrEP to royalty-free licenses across 120 countries. Read more here.

Dr. Reddy's expands collaboration with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention

Dr. Reddy’s Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement builds on Dr. Reddy’s existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention and treatment and reflects the continued confidence between the […]